NDEV Posts Steady Q2 2026 Revenue Growth; Self-Funded Model Yields 8.8% Debt-to-Equity Ratio

About this update from Novus Acquisition & Development Corp.

MIAMI, FLORIDA - August 25, 2026 ( NEWMEDIAWIRE ) - Novus Acquisition & Development Corp. (OTC: NDEV), doing business as Novus Cannabis MedPlan, today announced the release of its Q2 2026 Interim Report. The disclosure confirms consistent revenue growth and a defensive capital structure designed to insulate equity from the systemic debt crisis currently affecting plant-touching operators. Financial & Operational Highlights Industry Context: Structural Insulation from the "Wall of Debt" The U.S. cannabis industry is currently approaching a severe financial bottleneck, with an estimated $6 billion in expensive, hard-to-refinance debt coming due for plant-touching operators by the end of 2026. For many multi-state operators, the inability to refinance on favorable terms will likely result in lenders converting their debt into equity, forcing massive dilution upon existing shareholders. Novus operates completely outside this vulnerable paradigm. By functioning strictly as a health insurance carrier utilizing an HMO-style commerce model, NDEV does not cultivate, process, distribute, or sell the cannabis plant directly. Operating under this non-touch framework allows the company to eliminate substantial capital expenditures and safeguard against the burdensome debt obligations that MSOs face. Reimbursement Strategy & The "Affordability Gap" By deploying a specialized reimbursement framework, NDEV transforms standard operational overhead into a new revenue stream of reimbursement for cannabis businesses, facilitating capital recoupment at the supply chain's point of origin to offset consumer discounts and enhance operator margins. Management Commentary "Through the integration of cannabis benefits into health coverage models, we are strategically transforming the MedPlan from an optional expense into an essential financial utility and a new revenue source for the cannabis businesses across both medicinal and adult-use consumer segments," stated Frank Labrozzi, CEO of Novus. "This structural approach enhances consumer retention and systematically mitigates the high churn rates typically seen across traditional insurance and retail cannabis industries." Consumer Migration & Regulatory Support Factors Future growth centers on converting high-volume recreational consumers into long-term registered policyholders. By leveraging the arbitrage between heavily taxed recreational sales and our medical plan's cost-containment strategy, we are effectively evolving the Novus Cannabis MedPlan from a discretionary purchase into an essential financial necessity for the cannabis community. This strategic pivot not only delivers reliable retail foot traffic to our commercial partners but also positions Novus for sustained market expansion, ensuring a robust, scalable future for our shareholders as we continue to redefine the landscape of cannabis-inclusive health plans. About Novus Further Research: Novus Acquisition & Development Corp. (NDEV) operates as a premier health insurance carrier, seamlessly incorporating cannabis-inclusive coverage into standard health benefit models. Channeling operations through its wholly owned subsidiary, WCIG Insurance Service, Inc. CA License: 0K41569, NPN: 17687181, the organization delivers a structured, compliant administrative framework across U.S. medical and adult-use markets. With the cannabis market transitioning from traditional retail channels to institutional benefits programs, Novus delivers the core financial and analytical architecture essential for the Schedule III paradigm. By focusing on policyholder savings - offering 30% to 45% member discounts alongside point-of-sale tax mitigation - Novus establishes the benchmark for managed cannabis solutions, offered via individual or group coverage and fully integrable into carrier health plans. Forward-Looking Statements This release includes forward-looking statements, which are based on certain assumptions and reflect management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include general global economic conditions; general industry and market conditions and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, includes codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. Dilution, if any, would be for the purposes of management taking stock in lieu of cash salary. Novus disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Additionally, this press release that is not statements of historical fact may be considered to be forward-looking statements. Written words such as "may," "will," "expect," "believe," "anticipate," "estimate," "intends," "goal," "objective," "seek," "attempt," or variations of these or similar words, identify forward-looking statements. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the near future. Corporate Media & Investor Contact: Company: Novus Acquisition & Development Corp. (DBA Novus Cannabis MedPlan) Department: Investor Relations & Public Relations Website: https://getnovusnow.com/investor-relations Phone: 855-228-7355 Email: Investor Relations: [email protected]

View stock analysis, news, and events for Novus Acquisition & Development Corp.